Rationale: Tissue factor pathway inhibitor (TFPI) is a potent regulator of the tissue factor pathway and is found in plasma in association with lipoproteins. Objective: To determine the role of TFPI in the development of atherosclerosis, we bred mice which overexpress TFPI into the apolipoprotein E-deficient (apoE Key Words: atherosclerosis Ⅲ coagulation Ⅲ murine models Ⅲ tissue factor Ⅲ lipoproteins T issue factor (TF) pathway inhibitor (TFPI), a Kunitz-type serine protease inhibitor, is an endogenous inhibitor of TF-mediated coagulation. TFPI suppresses factor Xa generation by binding via its Kunitz 1 domain to the TF:FVIIa catalytic complex and via its Kunitz 2 domain to factor Xa. 1 The formation of a quaternary TF:VIIa:TFPI:Xa complex dampens ongoing FXa generation. Additionally, TFPI also has been shown to regulate coagulation by inducing the internalization and degradation of TF:VIIa complex on cell surfaces. [2] [3] [4] TFPI is expressed in many cells relevant to atherosclerosis including platelets, endothelial cells, vascular smooth muscle cells, and monocyte/macrophages. [5] [6] [7] [8] [9] In human carotid plaques, the level of TFPI expression is inversely associated with TF activity, suggesting a local regulatory role. 10 In plasma, TFPI exists in small quantities (Ͻ5%) as a free full-length protein but is predominantly associated with lipoproteins. 11-13 Lipoprotein-associated TFPI has been shown to have less anticoagulant activity than free TFPI. 13 TFPI is cleared from the plasma by binding the low-density lipoprotein receptor-related protein and heparin sulfate proteoglycans. 14, 15 It has been previously shown that the carboxyl terminus of TFPI (TFPIct) can bind lipoproteins 16 -18 and is a ligand for cell surface receptors including the very-low-density lipoprotein (VLDL) receptor. 19 Vascular overexpression of TFPI has been shown to reduce acute thrombosis and neointimal formation following vascular injury in murine models. 20, 21 Similarly, TFPI haploinsufficiency increases the atherosclerotic burden and thrombotic tendency in wild-type and apoE-deficient backgrounds. 22, 23 Taken together, these findings suggest a potentially important role for TFPI in the development and progression of acute and chronic vascular disease.
T issue factor (TF) pathway inhibitor (TFPI), a Kunitz-type serine protease inhibitor, is an endogenous inhibitor of TF-mediated coagulation. TFPI suppresses factor Xa generation by binding via its Kunitz 1 domain to the TF:FVIIa catalytic complex and via its Kunitz 2 domain to factor Xa. 1 The formation of a quaternary TF:VIIa:TFPI:Xa complex dampens ongoing FXa generation. Additionally, TFPI also has been shown to regulate coagulation by inducing the internalization and degradation of TF:VIIa complex on cell surfaces. [2] [3] [4] TFPI is expressed in many cells relevant to atherosclerosis including platelets, endothelial cells, vascular smooth muscle cells, and monocyte/macrophages. [5] [6] [7] [8] [9] In human carotid plaques, the level of TFPI expression is inversely associated with TF activity, suggesting a local regulatory role. 10 In plasma, TFPI exists in small quantities (Ͻ5%) as a free full-length protein but is predominantly associated with lipoproteins. [11] [12] [13] Lipoprotein-associated TFPI has been shown to have less anticoagulant activity than free TFPI. 13 TFPI is cleared from the plasma by binding the low-density lipoprotein receptor-related protein and heparin sulfate proteoglycans. 14, 15 It has been previously shown that the carboxyl terminus of TFPI (TFPIct) can bind lipoproteins 16 -18 and is a ligand for cell surface receptors including the very-low-density lipoprotein (VLDL) receptor. 19 Vascular overexpression of TFPI has been shown to reduce acute thrombosis and neointimal formation following vascular injury in murine models. 20, 21 Similarly, TFPI haploinsufficiency increases the atherosclerotic burden and thrombotic tendency in wild-type and apoE-deficient backgrounds. 22, 23 Taken together, these findings suggest a potentially important role for TFPI in the development and progression of acute and chronic vascular disease.
To further define the role of TFPI in vascular disease, we bred mice in which a murine TFPI transgene was expressed under the control of the SM22␣ promoter 24, 25 into the apoE Ϫ/Ϫ background. As expected, TFPI overexpression reduced plaque formation in this model. Unexpectedly, this decrease was associated with a reduction in plasma cholesterol suggesting a novel role for TFPI in lipid metabolism.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Materials
125 I-Human VLDL, human VLDL, and lipoprotein-deficient bovine calf serum were purchased from Biomedical Technologies Inc (Stoughton, Mass). Culture medium Dulbecco's modified PBS without Ca 2ϩ or Mg 2ϩ , Hank's balanced salt solution, and DMEM were purchased from Invitrogen (Carlsbad, Calif). Smooth muscle growth medium was from Lonza (Walkersville, Md). Soybean trypsin inhibitor, bovine serum albumin, heparin, heparinase I and III, collagenase type I, and elastase were purchased from Sigma-Aldrich Corp (St Louis, Mo). RAP (receptor related protein) was purchased from Innovative Research (Novi, Mich). Murine TFPI C-terminal 56mer peptide HRFNYTGCGGNNNNFTTRRRCLRS-CKTGLIKNKSKGVVKI-QRRKAPFVKVVYESIN (according to National Center for Biotechnology Information database accession no. NP-035706 from amino acids 251 to 306) was synthesized by Mayo Clinic protein core facility. The peptides were purified on a C-4 reversed-phase high-performance liquid chromatography column, and the purity was determined by high-performance liquid chromatography and confirmed by mass spectral analysis.
Murine Models

SM22␣-TFPI transgenic
ϩ/ϩ mice with C57BL/6 background were generated as previously described. 21 apoE-deficient mice on C57BL/6J background were purchased from Jackson Laboratory (Bar Harbor, MI). SM22␣-TFPI mice were cross bred into apoEdeficient mice to mice which were heterozygous (SM22␣ -TFPI ϩ/Ϫ / apoE ϩ/Ϫ ) for each allele. The double homozygous (SM22␣-TFPI ϩ/ϩ / apoE Ϫ/Ϫ ) mice were produced by backcrossing the heterozygous mice, which were identified by polymerase chain reaction (PCR) (for lack of wild-type apoE allele) and real-time PCR analysis (for TFPI transgene) of blood DNA samples. 21 Mice were maintained on standard chow unless noted. All procedures comply with the standards for care and use of animal subjects as stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, Md) and were approved by Mayo Clinic Institutional Animal Care and Use Committee.
Analysis of Atherosclerotic Lesions
Mice used in these experiments were 6 to 8 weeks old and 15 to 18g in weight. Groups of apoE Ϫ/Ϫ and SM22␣ -TFPI/apoE Ϫ/Ϫ mice were fed a high-fat Western diet (TD.88137, Harland, Madison, Wis). At the end of 5 weeks and 20 weeks of treatment, the mice were euthanized; aorta and blood samples were collected and analyzed. Additional methods are available in the Online Data Supplement.
Plasma Lipid and Lipoprotein Analysis
Plasma Samples
Blood samples from SM22␣ -TFPI/apoE Ϫ/Ϫ or apoE Ϫ/Ϫ mice (pooled groups of 6 to 8 mice/group) were obtained through retroorbital bleeding into EDTA-coated vials followed by centrifugation for 20 minutes at 3000 rpm at room temperature to obtain a final plasma volume of 1 mL. Plasma samples were kept frozen at Ϫ20°C until fast protein liquid chromatography (FPLC) was performed.
Cholesterol Assay
The WAKO Total Cholesterol E kit (Osaka, Japan) was used to determine the cholesterol concentration of each FPLC fraction. See the Online Data Supplement.
FPLC Instrumentation
FPLC was performed at 4°C using a Bio-Logic Pathfinder FPLC system interfaced with an automatic fraction collector (Bio-Rad, Hercules, Calif). 26 See the Online Data Supplement.
Cell Culture
To generate murine aortic smooth muscle cells (mASMCs), aortas were removed from mice and cleaned of adventitia under a dissecting scope. Murine embryonic fibroblasts (MEFs) and PEA13 cells were purchased from American Type Culture Collection and cultured according to provided protocols. See the Online Data Supplement.
125
I-VLDL Binding, Uptake, and Degradation by mASMCs, MEFs, and PEA13 Cells Studies of binding and uptake of 125 I-VLDL in mASMCs, MEFs, and PEA13 cells were performed using modified method of Datta et al. 27 See the Online Data Supplement.
Measurement of Murine TFPI in Plasma
Murine TFPI levels in plasma were measured by using murine TFPI-specific rabbit antibody and Protein Detector ELISA Kit. See the Online Data Supplement.
Small Interfering RNA Transfection
MEFs were transfected with small interfering RNA targeted to the VLDL receptor. See the Online Data Supplement.
Analysis of mRNA Expression of VLDL Receptor
Cells were harvested directly for RNA extraction by using RNeasy Plus Mini Kit (Qiagen). RNA extractions were reverse transcribed using SuperScript III first-Strand synthesis system (Invitrogen). Two microliters of cDNA was used as template to amplify with primer pair (forward: 5Ј-TGACGCAGACTGTTCAGACC-3Ј; reverse: 5Ј-GCCGTGGATACAGCTACCAT-3Ј) by PCR. The products of PCR were analyzed using agarose gel electrophoresis. For normalization of RNA loading, ␤-actin housekeeping gene was used as control.
VLDL-Peptide Complex Formation and Agarose Gel Electrophoresis
VLDL-peptide complex formation was tested using an agarose gel electrophoresis method. 28 Briefly, 10 g of VLDL and 10 g of VLDL plus various concentrations of TFPIct were incubated at room temperature for 1 hour. The samples of VLDL and VLDL-TFPIct mixtures were electrophoresed on a 0.7% agarose gel at a constant voltage of 100 V for 20 minutes. The gel was stained with Coomassie blue and photographed. 
Non-standard Abbreviations and Acronyms
In Vivo Administration of TFPIct
Administration of TFPIct in mice was performed at concentrations previously described for apolipoprotein mimetics. 29 ApoE Ϫ/Ϫ mice (8 to 12 weeks old) fed high-fat or normal chow were anesthetized, and blood samples were taken from the retroorbital sinus before the injection. In acute studies, 100 L of peptide (1 g/L in saline) was injected via tail vein. Saline was injected into the control group of mice. Blood samples (100 L) were taken from individual mice at 1 or 3 and 6 hours after injection, and the plasma was separated by centrifugation. Duplicate 10-L aliquots of each plasma sample were used for cholesterol determination. For chronic administration, 6-to 8-month-old apoE Ϫ/Ϫ mice were used, 100 L of peptide or saline was given intraperitoneally daily. Blood samples were taken at day 3 and 7 for cholesterol determination.
Statistical Analysis
All results are expressed as meansϮSEM. In all experiments, differences between control and treated groups were analyzed for statistical significance using a 1-way ANOVA, 2-way ANOVA, or an unpaired Student's t test (2-tailed). When applicable, a repeated measures analysis was performed. In the case of ANOVA, a post test comparison was used to compare all groups.
Results
To determine the effect of vascular overexpression of TFPI on the development of atherosclerosis, 6-to 8-week-old apoE
and SM22␣-TFPI/apoE Ϫ/Ϫ mice (nϾ10 for each group) were fed with a Western diet. After 20 weeks, atherosclerotic lesions were quantified in the aorta ( Figure 1A and 1B). Compared to apoE Ϫ/Ϫ mice, the extent of plaque surface area was significantly reduced in SM22␣-TFPI/apoE Ϫ/Ϫ mice ( Figure 1C ). There were no differences in plaque area between sexes in this model (data not shown).
Plasma cholesterol in both groups was measured from mice fed a high-fat diet for 5 weeks and 20 weeks. Surprisingly, the total cholesterol level in SM22␣-TFPI/apoE Ϫ/Ϫ mice was significantly lower at both time points than that in apoE Ϫ/Ϫ mice (Figure 2A ; PϽ0.01). Triglyceride levels were significantly lower at 5 weeks in the SM22␣-TFPI/apoE Ϫ/Ϫ mice compared with apoE Ϫ/Ϫ (165Ϯ31 mg/dL versus 269Ϯ28 mg/dL, PϽ0.014), but this difference was not significant at 20 weeks (185Ϯ40 versus 267Ϯ48 mg/dL, Pϭ0.21) ( Figure  2B ). On normal chow, the cholesterol levels were also decreased after 20 weeks (PϽ0.01) ( Figure 2A ). As with plaque development, no difference was noted between sexes. FPLC analysis on pooled samples confirmed that the differences between the mice were predominantly in the VLDL and low-density lipoprotein (LDL) fractions ( Figure 2C ). Baseline plasma cholesterol and triglyceride levels did not differ between SM22␣-TFPI and C57BL/6 mice ( Figure 2D and 2E). However, when fed a high-fat diet for 20 weeks, plasma cholesterol levels in SM22␣-TFPI mice were lower than C57BL/6 mice. These data suggest that vascular smooth muscle cell-directed overexpression of TFPI attenuates the hyperlipidemia induced by high-fat diet or apoE deletion.
The model system studied here allows for several potential mechanisms for the observed effects of TFPI overexpression on plasma cholesterol levels. These mechanisms might include differences in feeding habits or dietary absorption of lipid between mice. To that end, the SM22␣-TFPI mice are developmentally normal and have normal body weight and lifespan, which would not be supportive of that mechanism.
An alternative mechanism would be that the transgene might be involved in affecting lipoprotein levels.
To investigate the possibility that overexpression of TFPI alters local lipoprotein binding and internalization, we isolated mASMCs from SM22␣-TFPI and wild-type mice to study the effect of TFPI overexpression on 125 I-VLDL binding and internalization in these cells. At concentrations of 2 g and 10 g/mL of 125 I-VLDL, the surface binding of 125 I-VLDL on mASMCs isolated from SM22␣-TFPI mice was increased compared to that of cells isolated from wildtype mice (14Ϯ1 versus 11Ϯ0 for 2 g/mL and 51Ϯ0 versus 41Ϯ1 for 10 g/mL; Figure 3) . Also, the internalization of 125 I-VLDL in mASMCs isolated from SM22␣-TFPI mice was increased by approximately 50% compared with wildtype cells (93Ϯ11 versus 58Ϯ0 for 2 g/mL and 272Ϯ9 versus 181Ϯ8 for 10 g/mL). These data demonstrate that TFPI overexpression in mouse aortic smooth muscle cells (mASMCs) can regulate VLDL binding and internalization. However, as shown by Wamhoff et al, 30 the SM22␣ promoter is not expressed in advanced atherosclerotic lesions in apoEdeficient mice; therefore, the effect on lipoprotein handling may be attributable to overexpression of TFPI outside of the plaque itself.
We have previously demonstrated that SM22␣-TFPI mice have higher levels of vascular TFPI activity but similar levels of plasma TFPI activity. 21 However, using a murine specific ELISA, it was demonstrated that SM22␣-TFPI mice had increased levels of plasma TFPI antigen compared to wildtype mice (Figure 4 ). In addition, TFPI antigen was found in VLDL and LDL fractions (data not shown). The increased levels of TFPI in apoE-deficient mice parallel findings in humans with atherosclerosis and hyperlipidemia. 12 Again, similar to humans, we were unable to detect TFPI protein in the livers of transgenic or wild-type mice (data not shown). Thus, the SM22␣-directed overexpression of TFPI resulted in increased circulating TFPI antigen. Therefore, an endocrine/ paracrine mechanism for the lipoprotein effect was considered. Because TFPI circulates in lipoprotein fractions and the TFPIct is a known ligand of several cell surface receptors, we hypothesized that the TFPI, which is overexpressed in our model, may associate with VLDL and act to alter lipoprotein binding, uptake, and degradation. First, to determine whether TFPIct is capable of altering VLDL binding, uptake, and degradation, an in vitro model system was used. At a constant VLDL concentration, addition of TFPIct enhanced binding and uptake of VLDL in a concentration-dependent manner ( Figure 5A and 5B) in MEFs. When 1 g of TFPIct was added to VLDL, it resulted in a 15-fold increase in VLDL binding and 20-fold increase in VLDL internalization. At the highest 16:10 (wt/wt) ratio of TFPIct:VLDL, a 55-fold increase of VLDL binding and a 40-fold increase in internalization was observed. The effect of TFPIct on degradation of VLDL was also measured after incubation of the cells with or without TFPIct for 6 hours at 37°C. At the highest ratio we tested, 10 g of TFPIct mixed with 10 g of VLDL, the degradation rate increased by more than 100% ( Figure 5C ). The rate of VLDL degradation accelerated as the TFPIct:V-LDL ratio increased.
To define the mechanism by which TFPIct alters VLDL internalization, known TFPI receptors were studied. Knockdown of VLDL receptor expression by small interfering RNA partially attenuated TFPIct mediated binding and uptake of VLDL in these cells ( Figure 6 ). Furthermore, although RAP attenuated VLDL binding and uptake in the absence of TFPIct (Online Figure I, A) , the same dose of RAP did not affect the increase observed with TFPIct (Online Figure I, B) . Similarly the increase was only partially attenuated in cells deficient in lipoprotein receptor-related protein (PEA13) (Online Figure II) . These results indicate that known receptors for VLDL are only partially responsible for TFPIctmediated enhancement of VLDL binding and uptake in MEF. Because TFPI is known to bind heparin sulfate proteoglycans (HSPGs), similar studies were performed following treatment of MEFs with heparinase I and III. Heparinase treatment did not affect baseline VLDL binding and uptake in MEF but significantly reduced VLDL binding and uptake when TFPIct was added ( Figure 7 ). These results demonstrate that the HSPG pathway is the major route for the TFPImediated VLDL binding and subsequent uptake. Taken together, these data suggest that TFPIct enhances the binding and internalization of VLDL via the HSPG pathway in coordination with known receptors for VLDL.
TFPIct has a net positive charge, a feature shared with peptides that have been shown to be apolipoprotein E mimetics. 27 To determine whether TFPIct may associate and change the electrophoretic mobility of VLDL, VLDL was incubated with TFPIct at different weight ratios at room temperature for 1 hour and then analyzed by agarose gel electrophoresis (Online Figure III) . VLDL alone migrated toward the anode as a single band. The migration of mixtures of VLDL and TFPIct was impeded, and the degree depended on the ratio of VLDL to TFPIct. Mobility was impeded at molar ratios as low as 1:15. These results indicated that TFPIct associates with VLDL and alters its electrophoretic properties.
Finally, to determine whether the TFPIct is sufficient to reduce the cholesterol level in vivo, TFPIct was administrated intravenously into apoE-deficient mice fed high-fat or normal diet using concentrations of peptide previously used in studies of apolipoprotein mimetics. 29 In apoE-deficient mice after intravenous delivery of TFPIct, the cholesterol level was reduced significant after 6 hours compared with baseline in both fed Western diet and normal chow mice ( Figure 8A and 8B). Reductions were also observed more than 7 days time with daily IP injections in these older apoE-deficient mice fed normal chow ( Figure 8C ). Thus, systemic delivery of TFPIct is sufficient to reduce plasma cholesterol levels.
Discussion
This is the first report that suggests that overexpression of TFPI may regulate atherosclerotic plaque formation. The potential known mechanisms for such effects might include the antithrombotic effects of TFPI in this model 21 and its ability to block signaling via TF. 31 Unexpectedly, we identified that overexpression of TFPI reduced plasma cholesterol. It was this unexpected finding which became the focus of this study. TFPI was originally referred to as lipoproteinassociated coagulation inhibitor because of its association with lipoproteins. 32 Because TFPI is cleared from the blood through receptor-dependent and -independent mechanisms, a potential role in regulating lipoprotein clearance may not have been unexpected. Given the important roles of the TF pathway and lipoprotein metabolism in vascular disease, a biologically important association between the 2 remains intriguing. We have previously shown that the atherogenic lipoprotein Lp(a) can bind and inhibit TFPI activity through the binding of apo(a) to the TFPIct. 16 Overexpression of TFPI resulted in reductions in elevated plasma cholesterol levels in mice from apoE-deficient and wild-type backgrounds. Because TFPI has been shown to be a ligand of multiple cell surface receptors which also mediate lipoprotein clearance, we further demonstrated that the carboxyl terminus of murine TFPI can associate with and alter the distribution and degradation of VLDL in vitro and lower plasma cholesterol acutely in vivo following systemic injection. Taken together, we suggest that overexpression of TFPI regulates atherosclerotic lesion formation and does so in part through lowering cholesterol through the association of TFPI with atherogenic lipoproteins. These findings provide insights into a novel noncoagulant function for TFPI.
The present data suggest that smooth muscle cell-directed overexpression of TFPI can alter cholesterol levels through autocrine or endocrine effects. As a secreted peptide, in vitro and in vivo models of overexpression of TFPI cannot distinguish the two. Analysis of mASMCs which express TFPI from the SM22␣ promoter demonstrated increased binding, uptake and degradation of VLDL. Our subsequent focus on the TFPIct was based on its known functionality. TFPIct was shown to associate with VLDL and change its electrophoretic properties, and administration of TFPIct increased cell binding, uptake, and degradation of VLDL in vitro. This effect was mediated through enhanced binding of VLDL to HSPGs in a coordinated fashion with members of the LDL receptor family. In addition, acute or daily systemic delivery of TFPIct is sufficient to lower plasma cholesterol levels.
Taken together, these findings define potential mechanisms for the observed effects of TFPI overexpression on lowering cholesterol in the setting of hyperlipidemia attributable to apoE deletion or hyperlipidemic feeding. TFPI, either on the cell surface or following secretion, binds lipoproteins and increases binding and clearance of these lipoproteins through receptor-dependent and HSPG-dependent mechanisms. This HSPG-dependent mechanism has been demonstrated to be important in MEFs [33] [34] [35] and has been shown to be the mechanism by which apoE mimetics act to lower cholesterol. 27 Previous studies suggest that TFPI plays an important role in pathogenesis of vascular thrombosis and atherosclerosis. 9,10,21-23, 40 Westrick et al have shown that systemic reduction of TFPI Kunitz 1 expression in mice increased atherosclerotic lesion formation and shortened the occlusion time following ferric chloride exposure in the carotid arteries of TFPI ϩ/Ϫ /apoE Ϫ/Ϫ mice. 22 In that study, plasma lipid levels were not reported. It should be noted that the deletion in those mice is specific for the Kunitz 1 domain which leaves the carboxyl terminus intact. Indeed, cholesterol levels in heterozygotic mice (K1 deletion) fed normal chow does not differ from wild-type mice (data not shown).
Plasma TFPI found in lipoprotein fractions in humans has less anti-FXa and TF:FVIIa activity compared with free TFPI. 11 In our animal model, in spite of detecting increased plasma TFPI antigen and increased vascular TFPI activity, we are unable to detect increased circulating TFPI activity. 21 Human models of TFPI deficiency, particularly defects in the carboxyl terminus, have not been described. In relatively small human studies, there is a positive correlation between circulating TFPI and VLDL levels. 12, [41] [42] [43] In this study, apoE Ϫ/Ϫ mice had higher levels of circulating TFPI antigen than did wild-type mice, suggesting a regulatory role of hyperlipidemia on TFPI expression. These data suggest a potentially important and complex interaction between TFPI and lipoproteins.
Human TFPIct has been shown to be important for its coagulant and noncoagulant properties. It is required for optimal inhibition of FXa. 44, 45 It is also required for TFPI binding to cells and cell surface receptors including the VLDL receptor 19 and heparin sulfate proteoglycans. 46 The carboxyl terminus has also been shown to mediate its interaction with lipoproteins. 16 -18 The broad functionality of the TFPIct is reminiscent of the multifunctional peptides intended to serve as apolipoprotein mimetics. 27, 47 These mimetics contain moieties that bind lipoproteins and residues that mimic apoE bind the VLDL receptor. Systemic infusion of these peptides lowers cholesterol acutely in a similar manner to the TFPIct. In addition to the functional similarities, both are positively charged, which may play a role in their functionality. In fact, the mechanism for the effect of these peptides has been determined to be through dual pathways: HSPG-mediated and receptor-mediated (similar to our findings).
Although we cannot exclude the known anticoagulant functions of TFPI in the attenuation of atherosclerosis in this model, our data support a novel noncoagulant function of TFPI based on the unique multifunctional properties of its carboxyl terminus. This functionality adds another potent dimension in which to consider the antiatherosclerotic effects of TFPI. As such, the opportunities to use this functionality to understand its role in pathophysiology and treatment of human disease remain.
